✉news HealthMedicine first seen 2 d ago, last 7 h ago, peak #8

Eli Lilly weighs move into aesthetic medicine as GLP-1 use grows

Original: Lilly explores aesthetic medicine opportunities as patients cope with effects of GLP-1 weight loss

Eli Lilly is exploring opportunities in aesthetic medicine, as growing numbers of patients taking its GLP-1 weight-loss drugs deal with side effects such as sagging or loose skin after rapid weight loss. The move would position the Indianapolis-based drugmaker to serve patients seeking procedures to address changes in appearance tied to medications like Zepbound and Mounjaro.

Why now: The explosive uptake of GLP-1 weight-loss drugs is creating a new market for treatments addressing their cosmetic side effects, and Lilly's potential entry signals a major business expansion.

Eli LillyGLP-1 drugsZepboundIndianapolis

Open on news →

Evidence

• Lilly explores aesthetic medicine opportunities as patients cope with effects of GLP-1 weight loss · Daily Journal
• Lilly explores aesthetic medicine opportunities as patients cope with effects of GLP-1 weight loss · Indianapolis Business Journal

API: https://socialmediatrends-api.osmike.com/v1/trends/2515066